Idera Pharmaceuticals Announces One-for-Eight Reverse Stock Split
July 27, 2018 11:58 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., July 27, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook
July 16, 2018 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., July 16, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals
July 10, 2018 16:01 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., July 10, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into...
Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis
June 12, 2018 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., June 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients...
Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2018 07:30 ET
|
Idera Pharmaceuticals, Inc.
- Data from Ongoing Phase 2 Study to be Presented at 1:15 PM CT at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting - - Of 21 patients evaluable for efficacy, 38% Overall...
Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 09, 2018 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., May 09, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting
April 26, 2018 07:00 ET
|
Idera Pharmaceuticals, Inc.
- ILLUMINATE 204 Data selected as subject of a poster discussion session to be held on Monday, June 4, 2018 at 4:45 PM CT – - Idera to host Investor/Analyst Event at ASCO on Monday, June 4, 2018 at...
Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting
April 17, 2018 07:00 ET
|
Idera Pharmaceuticals, Inc.
CHICAGO, April 17, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma
April 16, 2018 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Idera Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with BioCryst Pharmaceuticals
April 02, 2018 08:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera”), a clinical-stage biopharmaceutical company focused on the discovery, development and...